文献速递肿瘤 PET/CT核素与放射性配体治疗放射性药物与辐射防护

18F-PSMA-1007与68Ga-PSMA-11-HBED-CC的内照射剂量学比较

Comparison of Internal Dosimetry of 18 F-PSMA-1007 and 68 Ga-PSMA-11-HBED-CC.
PubMed 文献 · Clin Nucl Med · 2022-08-16

本研究纳入8例病理确诊前列腺癌患者,其中4例接受18F-PSMA-1007 PET/CT、4例接受68Ga-PSMA-11-HBED-CC PET/CT,比较两种示踪剂的生物分布与内照射剂量。18F-PSMA-1007全身有效剂量(1.46E-02 mSv/MBq)高于68Ga-PSMA-11-HBED-CC(1.03E-02 mSv/MBq),且膀胱清除较少;作者认为18F-PSMA-1007是回旋加速器生产的替代选择,可能成为计划接受177Lu-PSMA-617治疗患者的良好诊断替代。

要点

  • 18F-PSMA-1007全身有效剂量为1.46E-02 mSv/MBq,高于68Ga-PSMA-11-HBED-CC的1.03E-02 mSv/MBq。
  • 18F-PSMA-1007肾脏平均当量剂量最高(1.48E-01 mGy/MBq),其后为脾(1.06E-01 mGy/MBq)和肝(6.80E-02 mGy/MBq)。
  • 68Ga-PSMA-11-HBED-CC肾脏当量剂量最高(2.13E-01 mGy/MBq),其后为肝(3.03E-02 mGy/MBq)、脾(2.90E-02 mGy/MBq)、肾上腺(2.67E-02 mGy/MBq)和膀胱(1.89E-02 mGy/MBq)。

核心结论

  • 18F-PSMA-1007的全身有效剂量高于68Ga-PSMA-11-HBED-CC。
  • 18F-PSMA-1007的膀胱清除少于68Ga-PSMA-11-HBED-CC,可在无明显放射性尿液干扰下更好地判读前列腺床。
  • 18F-PSMA-1007是回旋加速器生产的、可替代发生器生产的68Ga-PSMA-11-HBED-CC的示踪剂,可能成为计划接受177Lu-PSMA-617治疗患者的良好诊断替代。

研究设计与样本

  • 共纳入8例病理确诊前列腺癌患者,其中4例接受18F-PSMA-1007 PET/CT,另4例接受68Ga-PSMA-11-HBED-CC PET/CT。
  • 通过计算SUV量化两种示踪剂在各器官的生物分布,所有患者均接受5点序列显像,采用基于OLINDA的剂量学计算关键器官当量剂量和全身有效剂量。

主要发现

  • 18F-PSMA-1007 PET在脑、泪腺、唾液腺、心脏、肺、肝、胆囊、脾、胰腺、肠、臀肌和骨髓的摄取高于68Ga-PSMA-11 PET。
  • 68Ga-PSMA-11-HBED-CC在肾脏和膀胱的SUV值高于18F-PSMA-1007。
  • 18F-PSMA-1007全身有效剂量为1.46E-02 mSv/MBq,高于68Ga-PSMA-11-HBED-CC的1.03E-02 mSv/MBq。
  • 18F-PSMA-1007平均当量剂量最高为肾脏(1.48E-01 mGy/MBq),其后为脾(1.06E-01 mGy/MBq)和肝(6.80E-02 mGy/MBq)。
  • 68Ga-PSMA-11-HBED-CC当量剂量最高为肾脏(2.13E-01 mGy/MBq),其后为肝(3.03E-02 mGy/MBq)、脾(2.90E-02 mGy/MBq)、肾上腺(2.67E-02 mGy/MBq)和膀胱(1.89E-02 mGy/MBq)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer (PCa) is the most common cancer in men worldwide. Targeting prostate-specific membrane antigen (PSMA) using radiopharmaceuticals has shown promising results for PCa imaging as well as theranostics. 68 Ga-based PSMA imaging is limited by production of small quantities by generator, and it has led to quest for cyclotron produced 18 F-based PSMA ligands. In the current study, we evaluated the biodistribution and internal dosimetry of 18 F-PSMA-1007 and compared it with 68 Ga-PSMA-11-HBED-CC. MATERIALS AND METHODS: A total of 8 patients with histopathologically proven PCa were included in the study, of whom 4 patients underwent 18 F-PSMA-1007, and the other 4 patients underwent 68 Ga-PSMA-11-HBED-CC PET/CT. The biodistribution of both tracers was quantified for different organs by computing SUVs. All the patients underwent 5-point serial imaging to compute equivalent dose to essential organs and whole-body effective dose using OLINDA-based dosimetry. RESULTS: The radiotracer uptake in brain, lacrimal gland, salivary gland, heart, lung, liver, gallbladder, spleen, pancreas, intestine, gluteal muscle, and bone marrow were found to be higher in 18 F-PSMA-1007 PET as compared with 68 Ga PSMA-11 PET. Kidney and urinary bladder showed higher SUV value on 68 Ga-PSMA-11-HBED-CC as compared with 18 F-PSMA-1007.The whole-body effective dose from 18 F-PSMA-1007 (1.46E-02 mSv/MBq) was higher than 68 Ga-PSMA-11-HBED-CC (1.03E-02 mSv/MBq). The highest mean equivalent dose from 18 F-PSMA-1007 was observed in the kidneys (1.48E-01 mGy/MBq), followed by spleen (mean, 1.06E-01 mGy/MBq) and liver (6.80E-02 mGy/MBq), whereas 68 Ga-PSMA-11-HBED-CC equivalent dose was maximum in the kidneys (2.13E-01 mGy/MBq), followed by liver (3.03E-02 mGy/MBq), spleen (2.90E-02 mGy/MBq), adrenals (2.67E-02 mGy/MBq), and urinary bladder (1.89E-02 mGy/MBq). CONCLUSION: Whole-body effective dose from 18 F-PSMA-1007 is higher compared with 68 Ga-PSMA-11-HBED-CC. 18 F-PSMA-1007 shows lesser urinary bladder clearance compared with 68 Ga-PSMA-11-HBED-CC, which can allow better interpretation of prostatic bed without significant radioactive urine interference. 18 F-PSMA-1007 is a cyclotron-produced alternative to generator-produced 68 Ga-PSMA-11-HBED-CC and can emerge as a good diagnostic surrogate for patients planned for 177 Lu-PSMA-617 therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Sharma P, Watts A, Singh H, et al. Comparison of Internal Dosimetry of 18 F-PSMA-1007 and 68 Ga-PSMA-11-HBED-CC. Clin Nucl Med. 2022. PMID: 35961365. doi:10.1097/RLU.0000000000004353

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。